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Mitochondrial Donation — Which Women Could Benefit?
To the Editor: Mitochondrial donation is a new 
in vitro fertilization–based technique that has 
recently been regulated and licensed by the Hu-
man Fertilisation and Embryology Authority 
(HFEA) for clinical use in the United Kingdom. 
Mitochondrial donation allows the replacement 
of mutated mitochondrial DNA (mtDNA) in hu-
man oocytes or zygotes, offering at-risk couples 
the chance of having their own healthy child. 
HFEA licensing requirements for mitochondrial 
donation specify that its use should be permitted 
for patients who are at substantial risk for trans-
mitting serious mtDNA disease in situations in 
which preimplantation genetic diagnosis is deemed 
inappropriate or likely to be unsuccessful. Pre-
dicting the risk of serious mtDNA disease in 
children and the likely success of preimplanta-
tion genetic diagnosis is complicated by singu-
lar aspects of mitochondrial genetics, including 
mtDNA heteroplasmy (i.e., the mix of mutated 
[pathogenic] and wild-type [normal] mtDNA 
within a cell), threshold effect (i.e., the level of 
mtDNA mutation load below which no disease 
symptoms emerge), and mitochondrial genetic 
bottleneck (i.e., the process that can lead to off-
spring being born with a range of different 
mutation loads).1
Preimplantation genetic diagnosis is suitable 
only for women who are expected to produce 
some eggs with low levels of mutated mtDNA 
and are therefore at lower risk for having a child 
with serious mtDNA disease. To evaluate the 
risk of disease transmission, we focused on the 
MT-TL1 mutation m.3243A→G (because inheri-
tance patterns are mutation-specific), the most 
common heteroplasmic mtDNA pathogenic vari-
ant associated with severe mtDNA disease (car-
ried by approximately one third of adults in our 
mitochondrial clinics). We identified 183 mother–
child pairs from 113 mothers (Table S1 in the 
Supplementary Appendix, available with the full 
text of this letter at NEJM.org).2,3 Using Bayesian 
methods (see the Supplementary Appendix), we 
forecasted the proportion of children with hetero-
plasmy levels that were expected to be no higher 
than 18%, a level associated with a 95% or greater 
chance of being clinically unaffected (although 
this chance might be lower for m.3243A→G) and 
a cutoff value aligning with current preimplanta-
tion genetic diagnosis embryo-transfer practice 
guidelines.4,5 We found marked variability in the 
children’s levels of m.3243A→G heteroplasmy 
(Fig. S1 in the Supplementary Appendix). We 
have used these data to predict likely pregnancy 
outcomes. Only one quarter of children born to 
mothers harboring a 50% load of m.3243A→G 
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are predicted to have heteroplasmy levels of 18% 
or lower (Fig. 1). For mothers with heteroplasmy 
levels of 90% or higher, the percentage of chil-
dren with 18% or lower heteroplasmy is only 
8%. The substantive variability in biologic trans-
mission, indicated by the many points outside 
the prediction intervals, is also a finding of rel-
evance in the counseling of affected women and 
the deliberations of regulators.
Our data show that the risk of having a clini-
cally affected child can be predicted on the basis 
of maternal m.3243A→G heteroplasmy. For some 
women, the number of oocytes required to pro-
duce an embryo with sufficiently low mutation 
load (≤18%), and hence the chance of a healthy 
child, may be prohibitively high for “successful” 
preimplantation genetic diagnosis — one that 
results in the birth of a healthy child who is at 
minimal risk for mtDNA disease.
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Figure 1. Percentage of Children Predicted to Have 18% or Lower 
 Heteroplasmy for a Given Maternal Heteroplasmy.
Each point represents the percentage of children predicted to have 18% 
or lower age‑corrected m.3243A→G heteroplasmy for each of 113 individual 
mothers, plotted against maternal heteroplasmy. The solid line represents 
the linear fit of these forecasts against maternal heteroplasmy (R2 = 0.44, 
P<0.001), and the shaded area indicates the 95% confidence interval of this 
regression line. The upper and lower prediction interval boundaries are indi‑
cated by the dashed (50%) and dotted (80%) lines. To achieve these fore‑
casts, the mean child heteroplasmy for each mother was predicted with a 
Bayesian mixed‑effect regression model, with maternal heteroplasmy as a 
predictor and mother’s identity as a random effect. Forecasts were obtained 
from the probability distribution for each mother, with the probability clos‑
est to 18% heteroplasmy reported as the percentage of children predicted 
to have heteroplasmy less than or equal to 18%. In addition to the data show‑
ing that a large number of oocytes would need to be screened for women 
with high mtDNA heteroplasmy, there is great variability around the line 
of best fit, suggesting that there will be many women for whom an oocyte 
with acceptable heteroplasmy cannot be found, despite the prediction.
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